EVNIN LUKE 4

What Happened

• Luke Evnin, a director of Werewolf Therapeutics, sold 44,679 shares on May 13, 2026 in open-market transactions. The sales were reported at a weighted average price of $0.54 per share for total proceeds of about $24,127. The reported per-share prices ranged from $0.5077 to $0.61. The disposition was effected pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-05-13; Transaction type: Sale (Code S); effected under a 10b5-1 plan dated March 26, 2026 (F1).
• Shares sold: 44,679; weighted average price: $0.54; price range: $0.5077–$0.61 (multiple trades) (F3).
• Proceeds: approximately $24,127.
• Breakdown of which affiliated accounts sold shares: AM LLC (4,787), BV 2014 (30,223), BV 2014(B) (2,016), AM BV2014 (1,040), MPM OIF (6,613) (F2).
• Reported holdings across those affiliated entities after the transaction total about 1,126,496 shares (AM LLC 120,693; BV 2014 762,031; BV 2014(B) 50,824; AM BV2014 26,227; MPM OIF 166,721) (F5).
• Relationship note: Evnin is affiliated with the selling entities (member/MD/manager) and disclaims beneficial ownership except to the extent of any pecuniary interest (F4).
• Filing timeliness: Reported with the same period date (2026-05-13); no late filing indicated.

Context

• The sale was planned under a Rule 10b5-1 program, which typically schedules trades in advance and is considered a routine way insiders monetize holdings; such planned sales generally do not, by themselves, indicate a change in insider sentiment.